Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Barr closer to launching RLS generic
Barr Pharmaceuticals said a court backed its patent challenge of Mirapex, Boehringer Ingelheim's treatment for restless leg syndrome; Barr got FDA approval for a generic version in February. Mirapex sales came to $381 million for the 12 months ended in April, IMS Health figures show. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
